Lindenwold Advisors Neurocrine Biosciences Inc Transaction History
Lindenwold Advisors
- $204 Million
- Q3 2025
A detailed history of Lindenwold Advisors transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Lindenwold Advisors holds 2,241 shares of NBIX stock, worth $324,631. This represents 0.15% of its overall portfolio holdings.
Number of Shares
2,241
Previous 2,216
1.13%
Holding current value
$324,631
Previous $278,000
12.95%
% of portfolio
0.15%
Previous 0.15%
Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
725Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...